MEIRAGTX HOLDINGS PLC (MGTX)
Health Care · NASDAQ
A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and xerostomia, backed by proprietary viral vector manufacturing and riboswitch gene regulation technology.
What MEIRAGTX HOLDINGS PLC does
MeiraGTx is a clinical-stage genetic medicines company focused on developing therapies using localized delivery of genetic medicines to treat inherited and common diseases with high unmet need. The company has built comprehensive end-to-end manufacturing capabilities, including two GMP-licensed viral vector production facilities in London and Shannon, and a proprietary manufacturing platform optimized over 9+ years. Beyond gene therapy, the company has developed a transformative riboswitch gene regulation platform enabling precise, oral dose-responsive control of gene expression for metabolic peptides, cell therapy, and pain management.
Themes: ["Gene therapy / genetic medicines","Viral vectors and capsid engineering","Ophthalmology / inherited retinal disease","Parkinson's disease","Riboswitch technology / synthetic gene regulation","GLP-1 delivery systems","CAR-T cell therapy","Biomanufacturing / GMP manufacturing","Metabolic peptide therapeutics","Pain management / neurology"]
Fundamentals
- Price$13.94 as of 2026-07-09 close
- Market cap$1.3B as of 2026-07-10
- 1-year return+66.5% as of 2026-07-09 close
- Net margin-151.1% as of 2026-07-10
- Gross margin+95.4% as of 2026-07-10
- ROE-315.6% as of 2026-07-10
- Debt / equity24.92 as of 2026-07-10
- Revenue growth (YoY)+131.1% as of 2026-07-10
- Revenue CAGR (3y)+141.0% SEC XBRL
- Beta1.25 as of 2026-07-10
Key risks (from latest filing)
["Clinical stage company with no approved products and unprofitable operations (net margin -151%); success depends entirely on regulatory approval and clinical efficacy of late-stage pipeline candidates","Dependence on strategic partnerships (Janssen, Eli Lilly, Hologen) for funding and commercialization; changes in partner strategy or funding could materially impact development timelines","Manufacturing complexity and regulatory risk; GMP facility compliance failures or supply disruptions could delay or prevent product launches"]
Competitors & peers
- Spark Therapeutics (ONCE)
- Audentes Therapeutics (now part of Astellas)
- Regenxbio (RGNX)
- uniQure (QURE)
- Sangamo Therapeutics (SGMO)
- Gensight Biologics (part of Novartis)
- Eli Lilly (LLY) - ophthalmology genetic medicine collaboration partner
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.